1 Schouten, LJ, Rutten’ J, Huveneers, HA et al. Incidence fo brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, lung and melanoma. Cancer 2002 : 94 : 2698-2705
2 Patanaphan, V, Salazar, OM, Risco, R. Breast cancer : metastatic patterns and their prognosis. South Med J 1988 ; 81 (9) : 1109-1112
3 Schouten, LJ, Rutten’ J, Huveneers, HA et al. Incidence for brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, lung and melanoma. Cancer 2002 : 94 : 2698-2705
4 Nguyen, TD, Abrey, LE. Brain metastases : Old Problem, New Strategies. Hematol Oncol Clin N Am 21, 2007; 369-388
5 Delattre, JY, Krol, G, Thaler, HT et al. Distribution of brain metastases. Arch Neurol 1988 : 45 : 741-744
6 Chang, EL, Wefel, JS, Maor, MH et al. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 2007; 60 : 277-283;
7 Guide des soins palliatifs. Association des pharmaciens en établissements du Québec, 2008.
8 Strollo DC, Rosado-de-Christenson ML, Jett JR. Primary mediastinal tumors : Part II. Tumors of the middle and posterior mediastinum. Chest.1997;112:1344 -1357.
9 Shaham, D, Skilakaki, MG, Goitein, O. Imaging of the mediastinum : applications for thoracic surgery. Thorac Surg Clin 2004 ; 14 : 25.
10Eren S, Karaman A, Okur A ; The superior vena cava syndrome caused by malignant disease. Imaging with multi-detector row CT.Eur J Radiol. 2006;59(1) : 93.
11 Grillo, HC, Ojemann, RG, Scannell, JG, et al. Combined approach to « dumbbell » intrathoracic and intraspinal neurogenic tumors. Ann Thorac Surg 1983 ; 36 : 402.
12 Ackerman NB, Lien WM, Kondi ES, et al. The blood supply of experimental liver metastases. Distribution of hepatic artery and portal vein blood to ‘small’ liver metastases. Distribution of hepatic artery and portal vein blood to ‘small’ and ‘large’ tumors. Surgery. 1969;66:1067 –72
13 Noone TC, Semelka RC, Balci NC, Graham ML. Common occurrence of benign liver lesions in patients with newly diagnosed breast cancer investigated by MRI for suspected liver metastases. J Magn Reson Imaging. 1999;10:165
14Chezmar JL, Rumancik WM, Megibow AJ, Hulnick DH, Nelson RC, Bernardino ME. Liver and abdominal screening in patients with cancer: CT versus MR imaging. Radiology. 1988;168:43 –7
15Oliva, MR, Saini, S ; Liver cancer imaging : role of CT, MRI, US et PET. Cancer Imaging. 2004 2; 4 : S42-S46
16Hopper KD, Singapuri K, Finkel A. Body CT and oncologic imaging. Radiology. 2000;215:27 –40.
17Kulinna C, Helmberger T, Kessler M, Reiser M. Improvement in diagnosis of liver metastases with the multi-detector CT. Radiologe. 2001;41:16 –23.
18Baron RL. Understanding and optimizing use of contrast material for CT of the liver. Am J Roentgenol. 1994;163:323 –31
19Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using non-invasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002;224:748 –56
20Kalva S, Sahani D, Ryan D, Fishman A, Hahn P, Saini S. RSNA 2003 Gastrointestinal Session, Scientific Papers. Radiological Society of North America; Detection of liver metastases from GI cancer: comparison of high-resolution Mn-DPDP contrast-enhanced MRI and FDG–PET.
21Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3) : 205-16.
22De Sio M, Autorino R, Di Lorenzo G, Damiano R, Cosentino L, De Placido S, D'Armiento M. Adrenalectomy: defining its role in the surgical treatment of renal cell carcinoma. Urol Int. 2003;71:361 -7.
23Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003;149:273 -85. 14 Kumar R, Xiu Y, Yu JQ, Takalkar A, El-Haddad G, Potenta S, et al. 18F
24Mayo-Smith, WW, Boland, GW, Noto, RB, Lee, MJ. State of the art adrenal imaging. Radiographics 2001; 21(4) : 995-1912
25Blake, MA, Kalra, MK, Sweeney, AT, Lucey, BC, Maher, MM, Sahani, DV, Halpern, EF, Mueller, PR, Hahn, PF, Boland, GW. Distinguishing benign from malignant adrenal masses : multi-detector row CT protocol with 10 minute delay. Radiology 2006 238(2) : 578-585
26Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State-of-the-art adrenal imaging. Radiographics 2001;21:995 -1012.
27Haider MA, Ghai S, Jhaveri K, Lockwood G. Chemical shift MR imaging of hyperattenuating (>10 HU) adrenal masses: does it still have a role? Radiology 2004;231:711 -6.
28Krebs, TL, Wagner, BJ. MR Imaging of the adrenal gland : radiologic-pathologic correlation ; Radiographics, 1998 18(6) : 1425-1440
29The diagnosis and treatment of lung cancer ; National Institute for Clinical Evidence : NCI; United Kingdom ; 2005;
30Uberoi, J, Munver, R. Surgical management of metastases to the adrenal gland : open, laparoscopic, and ablative approaches. Curr Urol Rep 2009 10(1) : 67-72
31Hanks et al, Oxford Textbook of Palliative Medicine, 4e édition ; 2010
32Schoenlaub P, Sarrau, A, Grosshans, E, Heid, E, Cribier, B; Survival after cutaneous metastasis : a study of 200 cases Dermatol Venereol. 2001; 128(12) : 1310-1315
33Baines, M. Pathophysiology and management of malignant bowel obstruction. Dans Doyle, D, Hanks, GW, MacDonald, N, Cherny, N. Oxford textbook of palliatie medicine. 2e edition; New York : OxfortdUniversity Press ; 1998. pp 526-534
34Ripamonti, C, Mercadante, S. Pathophysiology and management of malignant bowel obstruction. Dans Doyle, D, Hanks, GW, MacDonald, N, Cherny, N, Calman, K. Oxford textbook of palliatie medicine. 3eedition; New York : Oxford University Press ;2004. Section 8 »3 »4, pp 496-506
35Direction de la lutte contre le Cancer- Février 2006 Québec Guide sur le traitement de la carcinomatose péritonéale par cytoréduction chirurgicale et chimiothérapie hyperthermique intrapéritonéale peropératoire Élaboré par le Comité de l’évolution des pratiques en oncologie CÉPO)
http://www.bibliotheque.assnat.qc.ca/01/mono/2006/02/838763.pdf
36Ripamonti, C, Fagnoni, E, Magni, A. Management of symptoms due to inoperable bowel obstruction. Tumori 2005; 91 : 233-236
37Trempe, D, Dion, D, Dechêne, G. L’occlusion intestinale chez le patient atteint de cancer. Le médecin du Québec 2006; 41 : 63-68
38Direction de la lutte contre le Cancer- Février 2006- Québec
Guide sur le traitement de la carcinomatose péritonéale par cytoréduction chirurgicale et chimiothérapie hyperthermique intrapéritonéale peropératoire
Élaboré par le Comité de l’évolution des pratiques en oncologie (CÉPO)
http://www.bibliotheque.assnat.qc.ca/01/mono/2006/02/838763.pdf
39Fueur, DJ, Broadley, KE, Shepherd, JH, Barton, DP. Systematic review of surgery in malignant bowel obstruction in advanced gycnecological and gastrointestinal cancer. The Systematic Review Steering Committee. Gynecol Oncol 1999; 75 : 313
40Ripamonti, C, Twycross, R, Baines, M, Bozetti, F et al. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care, Cancer 2001; 9(4) : 223-233.
41Trempe, D, Dion, D, Dechêne, G. L’occlusion intestinale chez le patient atteint de cancer. Le médecin du Québec 2006; 41 : 63-68
42Guide pratique des soins palliatifs : Regroupement des pharmaciens en établissements. APES. 2008; pp 87-91
43Major, P, Figueredo, V, Tandan, V, Bramwell, V, et al. The role of octreotide in the management of patients with cancer. Practice Guideline report # 12-7. Program in evidence-based-care. A Cancer Ontario program 2004. Pp 12-9.
www.cancercare.on.ca
44Guide pratique des soins palliatifs : Regroupement des pharmaciens en établissements. APES. 2008; pp 85-90, pp 197-206
45APES- Regroupement des pharmaciens du Québec en établissement de Santé; Guide pratique des soins palliatifs : gestion de la douleur et des autres symptômes. 2008; carcinomatose; pp 197-206
46Mini-guide de Palli-Science; www.maisonvictro-gadbois.com. Aller sur www.palli-science.com
Produit par la maison Victor Gadbois; Saint Mathieu de Beloeil; Ce guide de thérapeutique en soins palliatifs est mis à jour annuellement.
47 Section Guides des soins palliatifs infirmiers et médicaux. www.palli-science.com
48Parsons SL, Lang MW, Steele RJC. Malignant ascites : a 2 year review from a teaching hospital. Eur J Surg Oncol 996; 22 : 237–239
49Ayantundee, AA, Parsons, SL ; Pattern and prognostic factors in patients with malignant ascites: a retrospective study; Annals of Oncology 18 : 945–949, 2007
50Easson A, Bezjak A, Ross A et al. Changes in symptoms after paracentesis for symptomatic malignant ascites. J Clin Oncol 2005; 16 : 6071 (Suppl).
51Cruikshank, DP, Buchsbaum, HJ. Effects of rapid paracentesis. Cardiovascular dynamics and body fluid composition. JAMA 1973; 255:1361
52Ayantundee, AA, Parsons, SL ; Pattern and prognostic factors in patients with malignant ascites: a retrospective study; Annals of Oncology 18 : 945–949, 2007
53Runyon, BA. Paracentesis of ascitic fluid: A safe procedure. Arch Intern Med 1986; 146:2259
54McVay, PA, Toy, PT. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991; 13:164
55Mannucci, PM. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No. J Thromb Haemost 2006; 4:721
56Stephenson, J, Gilbert, J. The development of clinical guidelines on paracentesis for ascites related to malignancy. Palliat Med 2002; 16:213
57Rosenberg, SM. Palliation of malignant ascites. Gastroenterol Clin North Am 2006; 35:189 -199
58Pockros PJ, Esrason KT, Nguyen C et al. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 1992;103 : 1302–1306.
59Lee CW, Bociek G, Fraught W. A survey of practice in management of malignant ascites. J Pain Symptom Management 1998; 16 : 96–101.
60Antony VB, Loddenkempfer R, Astoul P, Boutin C, Goldstraw P, Hott J, Rodriguez Panadero F, Sahn SA. Management of malignant pleural effusions. Eur Respir J 2001;18:402 -19.
61Sahn SA. Pleural diseases related to metastatic malignancies. Eur Respir Dis 1997;10:1907 -13.
62Kvale, PA, Simoff, M, Prakash, U. American College of Chest Physician : Palliative Care; CHEST 2003; 123; 284S-311S.
63Oncolor : Site français de la région de Lorraine, présentant des référentiels médicaux d’investigation et de traitements, mis à jour, portant sur les principaux cancers et leurs symptômes; http://www.oncologik.fr
64Khaleeq, G, Musani, AI. Emerging paradigms in the management of malignant effusions. Respir Med 2008; 102(7) : 939-948.
65William H. Warren, Robert Kalimi, Lisa M. Khodadadian and Anthony W. Kim; Management of Malignant Pleural Effusions Using the Pleurx Catheter ; Ann Thorac Surg 2008;85:1049 -1055.
66William H. Warren, Robert Kalimi, Lisa M. Khodadadian and Anthony W. Kim; Management of Malignant Pleural Effusions Using the Pleurx Catheter ; Ann Thorac Surg 2008;85:1049 -1055.
67Kvale, PA, Simoff, M, Prakash, U. American College of Chest Physician : Palliative Care; Chest 2003; 123; 284S-311S.
68Spinazze, S, Caraceni, A, Schrijvers, D. Epidural spinal cord compression. Crit Rev Oncol Hematol 2005 ; 56(3) : 397-406
69Kim, RY. Extradural spinal cord compression from metastatic tumor. Ala Med 1990; 60(1-2) : 10-15
70MSSS- Traitement de la compression médullaire chez les patients atteints de cancer métastatique - Comité de l’évolution des pratiques en oncologie
(CEPO) – Québec Août 2011
www.msss.gouv.qc.ca/cancer
http://www.msss.gouv.qc.ca/sujets/prob_sante/cancer/index.php?lutte_cont...
71Kim, RY, Spencer, SA, Meredith RF, Weppelmann, B, Lee, JY, Smith, JW, Salter, MM. Extradural spinal cord compression : analysis of factors determining functionnal prognosis- prospective study. Radiology 1990; 176(1) : 279-282
72Dion, D, Trempe, D, Dechêne, G. La compression médullaire chez le patient atteint de cancer. Le Médecin du Québec. 2006; vol 41, no 11 : 57-61
73Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J.Clin.Oncol. 2005;23:2028 -37.
74Abrahm JL. Assessment and treatment of patients with malignant spinal cord compression. J.Support.Oncol. 2004;2:377 -88, 391.
75MSSS- Traitement de la compression médullaire chez les patients atteints de cancer métastatique - Comité de l’évolution des pratiques en oncologie
(CEPO) – Québec Août 2011
www.msss.gouv.qc.ca/cancer
http://www.msss.gouv.qc.ca/sujets/prob_sante/cancer/index.php?lutte_contre_le_cancer
76Schiff D. Spinal cord compression. Neurol.Clin. 2003;21:67 -86
77Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group.J.Clin.Oncol. 2005;23:2028 -37.
78MSSS- Traitement de la compression médullaire chez les patients atteints de cancer métastatique - Comité de l’évolution des pratiques en oncologie
(CEPO) – Québec Août 2011
www.msss.gouv.qc.ca/cancer
http://www.msss.gouv.qc.ca/sujets/prob_sante/cancer/index.php?lutte_contre_le_cancer
79MSSS- Traitement de la compression médullaire chez les patients atteints de cancer métastatique - Comité de l’évolution des pratiques en oncologie
(CEPO) – Québec Août 2011
www.msss.gouv.qc.ca/cancer
http://www.msss.gouv.qc.ca/sujets/prob_sante/cancer/index.php?lutte_contre_le_cancer
80MSSS- Traitement de la compression médullaire chez les patients atteints de cancer métastatique - Comité de l’évolution des pratiques en oncologie
(CEPO) – Québec Août 2011
www.msss.gouv.qc.ca/cancer
http://www.msss.gouv.qc.ca/sujets/prob_sante/cancer/index.php?lutte_contre_le_cancer
81Bruce DM, Heys SD, Eremin O. Lymphangitis carcinomatosa: a literature review. J R Coll Surg Edinb 1996; 41:7 -13.
82Musani AI. Treatment options for malignant pleural effusion. Curr Opin Pulm Med. 2009; 15(4) : 380-387
83Soares FA, Pinto AP, Landell GA, et al. Pulmonary tumor embolism to arterial vessels and carcinomatous lymphangitis: a comparative clinico-pathological study. Arch Pathol Lab Med1993 ; 117:827 –831
84Fraser RS, Muller NL, Colman N, et al. Section VI, Pulmonary neoplasms. Dans : Fraser and Pare's diagnosis of diseases of the chest. 4th ed. Philadelphia : Elsevier Health Sciences; 1999. p. 1390–7.
85Mathieson JR, Mayo JR, Staples CA, Müller NL. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology 1989;171 : 111–116
86Thomas, A, Lenox, R; Pulmonary lymphangitic carcinomatosis as a primary manifestation of colon cancer in a young adult ; CMAJ;2008; 179(4) : 338-340
87Mathieson JR, Mayo JR, Staples CA, Müller NL. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology 1989;171 : 111–116
88Stein, MG, Mayo, J. Muller, N, et al. Pulmonary lymphangitic spread of carcinoma : appearance on CT scans. Radiology; 1987; 162, 371-5
89Priyanka Prakash, Mannudeep K. Kalra, Amita Sharma, Jo-Anne O. Shepard and Subba R. Digumarthy ; FDG PET/CT in assessement of pulmonary lymphangitic carcinomatosis. American Roentgen Ray Society ; 2010 vol. 194 no. 1 231-236
90Guide pratique des soins palliatifs;2008; Regroupement des pharmaciens en établissement du Québec; APES, Les symptômes respiratoires- pp 223- 238
91Ripamonti C, Fusco F. Respiratory problems in advanced cancer. Support Care Cancer 2002; 10 : 204-216
92Booth, Wade R, Johnson M, Kite S, Swannick M, Anderson H; Expert Working Group of the Scientific Committee of the Association of Palliative Medicine. The use of oxygen in the palliation of breathlessness. A report of the expert working group of the scientific committee of the association of palliative medicine. Respir Med 2004; 98 : 66-77.
93Supportive care in respiratory disease. Edited by Ahmedzai SH and Muers FM. Oxford University Press, 2005
94Kesari, S, Batchelor, TT. Leptomeningeal metastases. Neurol Clin 2003; 21:25.
95Straathof, CS, de Bruin, HG, Dippel, DW, Vecht, CJ. The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol 1999; 246:810.
96Omuro, AM, Lallana, EC, Bilsky, MH, DeAngelis, LM. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 2005; 64:1625.
97Roodman, Gd. Mechanisms of Bone Metastasis. N Engl J Med 2004 ; 350 (16) : 1655-1664
98Mundy, GR; Metastasis fo bone : causes, consequences and therapeutic opportunities ; Rev Cancer; 2002; 2 (8) : 584-593
99Lote, K et al. Bone metastases. Prognosis, diagnosis and treatment. Acta Radiologica oncology ; 1986; 406 : 227-232
100Kirkbride, P , Mackillop, WJ, Priestman, TJ, Browman, G, Gospodarowicz, M, Rousseau, P. The role of palliative radiotherapy for bone metastases. Review; Can J Oncol 1996; suppl 1 : 33-38
101Doyle-Hanks, Palliative Medicine, Oxford 2001, pp 119-120
102Coleman, RE. Skeletal Complications of Malignancy. Cancer 1997; 80 : 1588-1594
103Hillner, BF, Ingle JN et al. American Society of Clinical Oncology Guideline on Role of Biphosphonates in breast cancer. J Clin Onc 2000, 18 : 1378-1391
104Martinez-Zapata MJ, Roqué M, Alonso-Coello P, Català E. Calcitonin for metastatic bone pain. Cochrane database of systematic reviews. 2006. Issue 3.